血浆中肝源性游离核酸的生物学及其在液体活检中的应用
本综述讨论血浆中肝源性游离核酸的检测方法及癌症相关异常,涵盖单核苷酸突变、拷贝数异常、甲基化异常和DNA片段化模式改变,并探讨其在肝细胞癌检测、监测和管理中的潜在临床应用。
要点
- 基于游离DNA的无创产前检测胎儿染色体非整倍体已成功应用于临床,在数十个国家被每年数百万孕妇使用。
- 癌症相关异常包括单核苷酸突变、拷贝数异常、甲基化异常和DNA片段化模式改变,可在多种癌症患者游离DNA中检测到。
- 甲基化和片段组学模式分析已使游离DNA的组织来源得以确定。
核心结论
- 本综述讨论检测循环肝源性核酸及癌症相关异常的不同方法,及其在肝细胞癌检测、监测和管理中的潜在临床应用。
研究设计与样本
- 综述,围绕游离DNA液体活检的生物学基础与临床应用展开讨论。
主要发现
- 基于游离DNA的无创产前检测胎儿染色体非整倍体是游离DNA技术的首个成功应用,已改变临床实践并在数十个国家被每年数百万孕妇使用。
- 癌症相关异常包括单核苷酸突变、拷贝数异常、甲基化异常和DNA片段化模式改变,已在多种癌症患者的游离DNA中检测到。
- 甲基化和片段组学模式分析已使游离DNA的组织来源得以确定。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There is much global research interest surrounding the use of cell-free DNA (cfDNA) for liquid biopsies. cfDNA-based non-invasive prenatal testing for foetal chromosomal aneuploidies was the first successful application of cfDNA technology that transformed clinical practice - it has since been rapidly adopted in dozens of countries and is used by millions of pregnant women every year. Prompted by such developments, efforts to use cfDNA in other fields, especially for cancer detection and monitoring have been actively pursued in recent years. Cancer-associated aberrations including single nucleotide mutations, copy number aberrations, aberrations in methylation and alterations in DNA fragmentation patterns have been detected in the cfDNA of patients suffering from a wide variety of cancers. In addition, the analysis of methylation and fragmentomic patterns has enabled the tissue origin of cfDNA to be determined. In this review, different approaches for detecting circulating liver-derived nucleic acids and cancer-associated aberrations, as well as their potential clinical applications for the detection, monitoring and management of hepatocellular carcinoma, will be discussed.
引用
- Jiang P, Chan KCA, Lo YMD, et al. Liver-derived cell-free nucleic acids in plasma: Biology and applications in liquid biopsies. J Hepatol. 2019. PMID: 31004682. doi:10.1016/j.jhep.2019.04.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。